496 related articles for article (PubMed ID: 9374349)
1. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
[TBL] [Abstract][Full Text] [Related]
3. Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography.
Nichols TL; Kabalka GW; Miller LF; Khan MK; Smith GT
Med Phys; 2002 Oct; 29(10):2351-8. PubMed ID: 12408309
[TBL] [Abstract][Full Text] [Related]
4. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.
Chadha M; Capala J; Coderre JA; Elowitz EH; Iwai J; Joel DD; Liu HB; Wielopolski L; Chanana AD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):829-34. PubMed ID: 9531367
[TBL] [Abstract][Full Text] [Related]
5. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
Henriksson R; Capala J; Michanek A; Lindahl SA; Salford LG; Franzén L; Blomquist E; Westlin JE; Bergenheim AT;
Radiother Oncol; 2008 Aug; 88(2):183-91. PubMed ID: 18336940
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II.
Imahori Y; Ueda S; Ohmori Y; Sakae K; Kusuki T; Kobayashi T; Takagaki M; Ono K; Ido T; Fujii R
Clin Cancer Res; 1998 Aug; 4(8):1833-41. PubMed ID: 9717809
[TBL] [Abstract][Full Text] [Related]
8. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
Nariai T; Ishiwata K; Kimura Y; Inaji M; Momose T; Yamamoto T; Matsumura A; Ishii K; Ohno K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S348-50. PubMed ID: 19375930
[TBL] [Abstract][Full Text] [Related]
9. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study.
Bergenheim AT; Capala J; Roslin M; Henriksson R
J Neurooncol; 2005 Feb; 71(3):287-93. PubMed ID: 15735919
[TBL] [Abstract][Full Text] [Related]
10. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy.
Joel DD; Coderre JA; Micca PL; Nawrocky MM
J Neurooncol; 1999 Feb; 41(3):213-21. PubMed ID: 10359141
[TBL] [Abstract][Full Text] [Related]
11. Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results.
Coderre JA; Elowitz EH; Chadha M; Bergland R; Capala J; Joel DD; Liu HB; Slatkin DN; Chanana AD
J Neurooncol; 1997 May; 33(1-2):141-52. PubMed ID: 9151231
[TBL] [Abstract][Full Text] [Related]
12. The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma.
Kabalka GW; Nichols TL; Smith GT; Miller LF; Khan MK; Busse PM
J Neurooncol; 2003; 62(1-2):187-95. PubMed ID: 12749713
[TBL] [Abstract][Full Text] [Related]
13. Comments to article: Henriksson R et al., Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA) Radiother Oncol (2008).
H-Stenstam B
Radiother Oncol; 2008 Aug; 88(2):287-8; author reply 288. PubMed ID: 18617284
[No Abstract] [Full Text] [Related]
14. Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy.
Elowitz EH; Bergland RM; Coderre JA; Joel DD; Chadha M; Chanana AD
Neurosurgery; 1998 Mar; 42(3):463-8; discussion 468-9. PubMed ID: 9526978
[TBL] [Abstract][Full Text] [Related]
15. Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model.
Lin YC; Hwang JJ; Wang SJ; Yang BH; Chang CW; Hsiao MC; Chou FI
Anticancer Res; 2012 Jul; 32(7):2657-64. PubMed ID: 22753723
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity.
Coderre JA; Chanana AD; Joel DD; Elowitz EH; Micca PL; Nawrocky MM; Chadha M; Gebbers JO; Shady M; Peress NS; Slatkin DN
Radiat Res; 1998 Feb; 149(2):163-70. PubMed ID: 9457896
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I.
Imahori Y; Ueda S; Ohmori Y; Sakae K; Kusuki T; Kobayashi T; Takagaki M; Ono K; Ido T; Fujii R
Clin Cancer Res; 1998 Aug; 4(8):1825-32. PubMed ID: 9717808
[TBL] [Abstract][Full Text] [Related]
18. MicroPET-based pharmacokinetic analysis of the radiolabeled boron compound [18F]FBPA-F in rats with F98 glioma.
Chen JC; Chang SM; Hsu FY; Wang HE; Liu RS
Appl Radiat Isot; 2004 Nov; 61(5):887-91. PubMed ID: 15308163
[TBL] [Abstract][Full Text] [Related]
19. 4-Borono-2-
Ishiwata K
Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
[TBL] [Abstract][Full Text] [Related]
20. Hydroxylforms of p-boronophenylalanine as potential boron carriers on boron neutron capture therapy for malignant brain tumors.
Takagaki M; Ono K; Oda Y; Kikuchi H; Nemoto H; Iwamoto S; Cai J; Yamamoto Y
Cancer Res; 1996 May; 56(9):2017-20. PubMed ID: 8616843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
